Researchers Identify Potential AML Drug Target
A new mutation in human acute myeloid leukemia (AML) represents a valid therapeutic target.
Diagnosis & Disease Information
Adding Cladribine to Standard Induction Regimen Improves AML Survival
Investigators suggest the daunorubicin/cytarabine/cladribine regimen be considered the new standard of care as remission induction.
Long-Term Illness and Chronic Myelogenous Leukemia (CML): Where to Find Emotional Support
This fact sheet provides hints for managing the emotional challenges of coping with chronic myelogenous leukemia (CML) over time.
Multiple Myeloma Appointments: Making the Most of Office Visits
This fact sheet provides tips for patients with multiple myeloma cancer for improving communication with providers during visits.
Alemtuzumab + Methylprednisone Effective in TP53-Defective CLL
For patients with chronic lymphocytic leukemia (CLL) and deletion of TP53, alemtuzumab plus methylprednisolone is a highly effective induction regimen
Chemotherapy Benefits Subset of Childhood ALL Induction Failures
A subset of pediatric patients with acute lymphoblastic leukemia (ALL) who have precursor B-cell leukemia appear to have a better outcome with chemotherapy after failing remission-induction therapy.
Fractionated Doses of Gemtuzumab Ozogamicin Improves AML Outcomes
Fractionated lower doses of gemtuzumab ozogamicin allows safe delivery of higher cumulative doses and substantially improves outcomes in adults with de novo acute myeloid leukemia (AML).
Less Intensive Chemotherapy Recommended for Advanced Stage Hodgkin Lymphoma
Six cycles of BEACOPPescalated chemotherapy — vs. 8 cycles — followed by PET-guided radiotherapy should be the treatment of choice for patients with advanced stage Hodgkin’s lymphoma.
Multiple Myeloma Treatment Options Expanding
Vorinostat (Zolinza) and Carfilzomib (PR-171) have shown promise as new treatment options for multiple myeloma patients.
Expanded Treatment Landscape for Multiple Myeloma
Oncologists who treat multiple myeloma patients have a large diversity of therapeutic agents at their disposable. The challenges of treatment-refractoriness and disease relapse have necessitated continuous development of novel therapeutic agents and repurposing of current standard therapies.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...